VRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Verona Pharma's Gross Profit for the three months ended in Dec. 2024 was $34.62 Mil. Verona Pharma's Revenue for the three months ended in Dec. 2024 was $36.66 Mil. Therefore, Verona Pharma's Gross Margin % for the quarter that ended in Dec. 2024 was 94.44%.
The historical rank and industry rank for Verona Pharma's Gross Margin % or its related term are showing as below:
During the past 13 years, the highest Gross Margin % of Verona Pharma was 93.89%. The lowest was 24.45%. And the median was 59.17%.
Verona Pharma had a gross margin of 94.44% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Verona Pharma was 0.00% per year.
The historical data trend for Verona Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verona Pharma Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 24.45 | - | 93.89 |
Verona Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | 90.34 | 94.44 |
For the Biotechnology subindustry, Verona Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Verona Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Verona Pharma's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Verona Pharma's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 39.7 | / | 42.279 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (42.279 - 2.582) | / | 42.279 | |
= | 93.89 % |
Verona Pharma's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 34.6 | / | 36.655 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (36.655 - 2.039) | / | 36.655 | |
= | 94.44 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Verona Pharma (NAS:VRNA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Verona Pharma had a gross margin of 94.44% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Verona Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Kathleen A. Rickard | officer: Chief Medical Officer | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Mark W Hahn | officer: Chief Financial Officer | 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517 |
David Zaccardelli | director, officer: President and CEO | 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
David R Ebsworth | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Christina Ackermann | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Martin Edwards | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Claire Poll | officer: General Counsel | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rishi Gupta | director, 10 percent owner | C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Access Industries Holdings Llc | 10 percent owner | C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
Ai Biotechnology Llc | 10 percent owner | C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Access Industries Management, Llc | 10 percent owner | 730 FIFTH AVENUE, NEW YORK NY 10019 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
James Aloysius Brady | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Lisa Deschamps | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
From GuruFocus
By GuruFocus News • 12-07-2024
By GuruFocus News • 02-26-2025
By GuruFocus News • 11-08-2024
By Marketwired • 01-07-2025
By GuruFocus News • 11-14-2024
By Marketwired • 02-27-2025
By GuruFocus News • 11-14-2024
By GuruFocus News • 02-15-2025
By GuruFocus News • 11-19-2024
By GuruFocus News • 11-27-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.